Results 151 to 160 of about 82,604 (202)

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer

Archives of Endocrinology and Metabolism
Inbar Finkel, Yasmin Korzets, Assaf Moore, Tara Coreanu, Aron Popovtzer, Hagit Shoffel-Havakuk, Gideon Bachar, Jobran Mansour, Chana Weiss, Eyal Robenshtok   +9 more
openaire   +1 more source

The multifaceted anti-cancer effects of BRAF-inhibitors. [PDF]

Oncotarget, 2019
Croce L, Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Radiosensitization by BRAF inhibitors

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2017
BackgroundIncreased skin toxicity during combination therapy with a BRAF inhibitor and radiation therapy has recently been reported.Material and MethodsWe present seven melanoma patients with non‐resectable stage III or IV disease and concomitant treatment with a BRAF inhibitor and radiation therapy.ResultsIn all patients, combination therapy yielded a
Strobel, Sophia Boyoung, Pätzold, Sylvie, Zimmer, Lisa, Jensen, Alexandra, Enk, Alexander, Hassel, Jessica Cecile   +5 more
openaire   +3 more sources

Overcoming Drug Resistance to BRAF Inhibitor

Bulletin of Mathematical Biology, 2020
One of the most frequently found mutations in human melanomas is in the B-raf gene, making its protein BRAF a key target for therapy. However, in patients treated with BRAF inhibitor (BRAFi), although the response is very good at first, relapse occurs within 6 months, on the average.
Friedman, Avner, Siewe, Nourridine
openaire   +2 more sources